SCHEMBL5452418

SCHEMBL5452418

NNCCc1ccc(C(=O)O)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.57
LMNA P02545 3/20 0.57
CYP3A4 P08684 2/20 0.57
KDM1A O60341 2/20 0.57
TSHR P16473 2/20 0.57
NPC1 O15118 1/20 0.57
CYP1A2 P05177 1/20 0.57
HTR1A P08908 1/20 0.57
ADRA2A P08913 1/20 0.57
CYP2C8 P10632 1/20 0.57
CYP2D6 P10635 1/20 0.57
CYP2C9 P11712 1/20 0.57
IDO1 P14902 1/20 0.57
NFKB1 P19838 1/20 0.57
MAOA P21397 1/20 0.57
PTGS1 P23219 1/20 0.57
SLC6A2 P23975 1/20 0.57
MAOB P27338 1/20 0.57
CYP2C19 P33261 1/20 0.57
ADRA1A P35348 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3654946 0.82 CA2 (0.52) ALDH1A1LMNANPC1RAB9AMAPT
SCHEMBL15743513 0.82 ALDH1A1 (0.52) ALDH1A1LMNATSHRMAPTRARB
SCHEMBL28416786 0.81 ST14 (0.56) ALDH1A1LMNANPC1CYP1A2CYP2D6
SCHEMBL70166 0.80 TSHR (0.67) ALDH1A1TSHRSMN1; SMN2MAPTRARB
Terephthalic Acid SCHEMBL4612225 0.80 TSHR (0.67) ALDH1A1TSHRSMN1; SMN2MAPTRARB
SCHEMBL7026171 0.80 TMEM97 (0.59) ALDH1A1LMNATSHRCYP1A2NFKB1
SCHEMBL1402894 0.79 KMT2A (0.60) ALDH1A1CYP3A4TSHRIDO1MAPT
SCHEMBL28066274 0.78 SIGMAR1 (0.57) ALDH1A1LMNANPC1RAB9AMAPT
Hydrochloric Acid SCHEMBL7132238 0.78 TSHR (0.63) ALDH1A1TSHRMAPTRARBTP53
SCHEMBL10604135 0.78 ST14 (0.61) ALDH1A1LMNANPC1CYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070037846-A1 Pyrazolidinedione derivatives ACTELION PHARMACEUTICALS, LTD. (CH) 2007-02-15 US disclosed
EP-1638540-A2 PYRAZOLIDINEDIONE DERIVATIVES AND THEIR USE AS PLATELET AGGREGATION INHIBITORS Actelion Pharmaceuticals Ltd. (CH) 2006-03-29 EP disclosed
WO-2005002574-A1 PYRAZOLIDINEDIONE DERIVATIVES AND THEIR USE AS PLATELET AGGREGATION INHIBITORS ACTELION PHARMACEUTICALS LTD (CH) 2005-01-13 WO disclosed
WO-2005000281-A2 PYRAZOLIDINEDIONE DERIVATIVES AND THEIR USE AS PLATELET AGGREGATION INHIBITORS ACTELION PHARMACEUTICALS LTD. (CH) 2005-01-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070037846-A1 Pyrazolidinedione derivatives P2RY1, P2RY4, P2RY2 ALDH1A1 1198/4885LMNA 2912/4885CYP3A4 394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.